Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Fostamatinib disodium (also known as R-788; R-935788; brand name: Tavalisse) is the prodrug form of the active metabolite R406. It is an orally bioactive and selective Syk inhibitor with anti-inflammatory activity. It inhibits Syk kinase with IC50 of 41 nM in a cell-free assay. As of 2018, Fostamatinib gained FDA approval to treat thrombocytopenia in adult patients with persistent or chronic immune thrombocytopenia (ITP). Fostamatinib strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Fostamatinib has displayed anti-inflammatory and immunomodulating activities.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
In Louvain rats, fostamatinib (R788) is highly bioavailable and rapidly absorbed. Following a single oral dose of R788 10 mg/kg or R406 20 mg/kg, the following results were observed after one hour: t1/2 = 4.2 hours; AUC0-16 hrs = 10618 ng*h/mL and 30650 ng*h/mL, respectively; Cmax = 2600 ng/mL and 6500 ng/mL, respectively. The complete conversion of R788 to R406 was shown by the absence of prodrug in plasma [1].
|
||
Animal Protocol |
|
||
References | |||
Additional Infomation |
Fostamatinib Disodium Anhydrous is the anhydrous form of fostamatinib disodium, an orally available Syk kinase inhibitor with potential anti-inflammatory and immunomodulating activities. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage. Syk kinase, widely expressed in hematopoietic cells, is a nonreceptor tyrosine kinase that is involved in coupling activated immunoreceptors to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis.
Fostamatinib Disodium is an orally available disodium salt of the Syk kinase inhibitor fostamatinib with potential anti-inflammatory and immunomodulating activities. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage. Syk kinase, widely expressed in hematopoietic cells, is a nonreceptor tyrosine kinase that is involved in coupling activated immunoreceptors to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis. See also: Fostamatinib (has active moiety). Drug Indication Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. |
Molecular Formula |
C23H24FN6NA2O9P
|
---|---|
Molecular Weight |
624.42
|
Exact Mass |
624.112
|
CAS # |
1025687-58-4
|
Related CAS # |
Fostamatinib;901119-35-5;Fostamatinib disodium hexahydrate;914295-16-2
|
PubChem CID |
25008120
|
Appearance |
White to yellow solid powder
|
LogP |
3.53
|
Hydrogen Bond Donor Count |
2
|
Hydrogen Bond Acceptor Count |
15
|
Rotatable Bond Count |
9
|
Heavy Atom Count |
42
|
Complexity |
893
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
HSYBQXDGYCYSGA-UHFFFAOYSA-L
|
InChi Code |
InChI=1S/C23H26FN6O9P.2Na/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4;;/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29);;/q;2*+1/p-2
|
Chemical Name |
sodium (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate
|
Synonyms |
Fostamatinib disodium hexahydrate; R788; R 788; R-788 sodium; Tamatinib Fosdium, R-935788; R935788; R-935788; R 935788; R935788 sodium. Fostamatinib sodium, prodrug of R-406.
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 0.5% CMC+0.25% Tween 80,pH6.5:30 mg/mL |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.6015 mL | 8.0074 mL | 16.0149 mL | |
5 mM | 0.3203 mL | 1.6015 mL | 3.2030 mL | |
10 mM | 0.1601 mL | 0.8007 mL | 1.6015 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00798096 | Completed Has Results | Drug: Fostamatinib Disodium | T Cell Lymphoma | Rigel Pharmaceuticals | March 2009 | Phase 2 |
NCT00923481 | Completed Has Results | Drug: Fostamatinib disodium | Head and Neck Neoplasms Pheochromocytoma |
National Cancer Institute (NCI) | April 2009 | Phase 2 |
NCT02077192 | Completed Has Results | Drug: Fostamatinib Disodium | Immune Thrombocytopenic Purpura | Rigel Pharmaceuticals | October 2014 | Phase 3 |
NCT00706342 | Completed Has Results | Drug: Fostamatinib Disodium / R935788 | Purpura, Thrombocytopenic, Idiopathic | Rigel Pharmaceuticals | January 2007 | Phase 2 |